Program
denatonium acetate monohydrate
Its studies are mostly in Hyperphagia · Obesity · Prader-Willi Syndrome, led by Aardvark Therapeutics.
Furthest: phase 3, since Feb 13, 20255 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aardvark Therapeutics | 50 open or running | phase 3since Feb 13, 2025 | Oct 19, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 19, 2021First study: phase 2 study in ObesityFirst studyNCT05121441 · 20 enrolled · United States
- Nov 30, 2021Phase 2 study in Prader-Willi SyndromeNCT05153434 · 19 enrolled · United States
- Jan 3, 2022Phase 2 study in ObesityNCT05215847 · 12 enrolled · United States
- Feb 13, 2025Phase 3 study in HyperphagiaNCT06828861 · 68 enrolled · United States, Australia, Canada and more
- Sep 21, 2025Phase 3 study in HyperphagiaNCT07197034 · 19 enrolled · United States, Australia, Canada and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07197034Hyperphagia · United States, Australia, Canada and more | 3 | Terminated | Apr 15, 2026 | 19 |
| NCT06828861Hyperphagia · United States, Australia, Canada and more | 3 | Terminated | May 7, 2026 | 68 |
| NCT05215847Obesity · United States | 2 | Completed | Feb 3, 2023 | 12 |
| NCT05153434Prader-Willi Syndrome · United States | 2 | Completed | Sep 24, 2024 | 19 |
| NCT05121441Obesity · United States | 2 | Completed | Nov 9, 2022 | 20 |
How it is read
Names in the registry
- “ARD-101”, 5 entries
Conditions, from the studies’ own filings
- Hyperphagia, 2 studies
- Obesity, 2 studies
- Prader-Willi Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.